

Marc Peeters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9560206/publications.pdf>

Version: 2024-02-01

250
papers

20,487
citations

25014

57
h-index

11047

137
g-index

257
all docs

257
docs citations

257
times ranked

20847
citing authors

#	ARTICLE	IF	CITATIONS
1	Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1626-1634.	0.8	3,032
2	Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1658-1664.	0.8	1,828
3	Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1909-1919.	13.9	1,027
4	Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2011, 378, 2005-2012.	6.3	938
5	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4706-4713.	0.8	909
6	Controlled trial of metronidazole treatment for prevention of crohn's recurrence after ileal resection. <i>Gastroenterology</i> , 1995, 108, 1617-1621.	0.6	731
7	Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. <i>Gastroenterology</i> , 1999, 116, 22-28.	0.6	450
8	Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. <i>Gastroenterology</i> , 2001, 120, 1323-1329.	0.6	394
9	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. <i>Lancet Oncology, The</i> , 2014, 15, 569-579.	5.1	384
10	Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 3687-3694.	0.8	377
11	Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 730-734.	0.2	350
12	The value of serologic markers in indeterminate colitis: A prospective follow-up study. <i>Gastroenterology</i> , 2002, 122, 1242-1247.	0.6	340
13	Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab. <i>Journal of Clinical Oncology</i> , 2009, 27, 5068-5074.	0.8	325
14	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology, The</i> , 2017, 18, 1159-1171.	5.1	293
15	SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1723-1731.	0.8	289
16	Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4450-4456.	0.8	254
17	Histopathologic Validation of Lymph Node Staging With FDG-PET Scan in Cancer of the Esophagus and Gastroesophageal Junction. <i>Annals of Surgery</i> , 2000, 232, 743-752.	2.1	241
18	Comparative Analysis of Dynamic Cell Viability, Migration and Invasion Assessments by Novel Real-Time Technology and Classic Endpoint Assays. <i>PLoS ONE</i> , 2012, 7, e46536.	1.1	229

#	ARTICLE	IF	CITATIONS
19	Mutant <i>KRAS</i> Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab. <i>Journal of Clinical Oncology</i> , 2013, 31, 759-765.	0.8	219
20	Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1902-1912.	3.2	214
21	Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 2913-2919.	3.2	188
22	Comparison of Magnetic Resonance Imaging and Histopathological Response to Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 2842-2852.	0.7	187
23	Clinical Usefulness of <i>EGFR</i> Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent <i>In situ</i> Hybridization Study. <i>Clinical Cancer Research</i> , 2008, 14, 5869-5876.	3.2	171
24	Anti-Saccharomyces Cerevisiae Antibodies (ASCA), Phenotypes of IBD, and Intestinal Permeability: A Study in IBD Families. <i>Inflammatory Bowel Diseases</i> , 2001, 7, 8-15.	0.9	156
25	Analysis of <i>KRAS</i> / <i>NRAS</i> Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5469-5479.	3.2	152
26	Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. <i>Gastroenterology</i> , 2001, 120, 827-833.	0.6	136
27	Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and <i>KRAS</i> status in patients receiving panitumumab monotherapy. <i>Cancer</i> , 2009, 115, 1544-1554.	2.0	127
28	Liquid biopsies in lung cancer: The new ambrosia of researchers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 539-546.	3.3	123
29	Inpatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2861-2868.	0.8	117
30	Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1493-1500.	1.9	117
31	Inflammatory bowel disease in spouses and their offspring. <i>Gastroenterology</i> , 2001, 120, 816-819.	0.6	109
32	Effect of Long-Term Oral Glutamine Supplements on Small Intestinal Permeability in Patients With Crohn's Disease. <i>Journal of Parenteral and Enteral Nutrition</i> , 1999, 23, 7-11.	1.3	108
33	Tumor Cells and Tumor-Associated Macrophages: Secreted Proteins as Potential Targets for Therapy. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-12.	3.3	108
34	Cachexia in cancer: what is in the definition?. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000097.	1.1	97
35	Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. <i>Oncotarget</i> , 2016, 7, 28748-28760.	0.8	95
36	The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Perioperative Chemotherapy (HIPEC) with Oxaliplatin: A Belgian Multicentre Prospective Phase II Clinical Study. <i>Annals of Surgical Oncology</i> , 2012, 19, 2186-2194.	0.7	94

#	ARTICLE	IF	CITATIONS
37	Probiotics enhance the clearance of human papillomavirus-related cervical lesions. <i>European Journal of Cancer Prevention</i> , 2013, 22, 46-51.	0.6	93
38	Large-scale analysis of DNFA5 methylation reveals its potential as biomarker for breast cancer. <i>Clinical Epigenetics</i> , 2018, 10, 51.	1.8	86
39	Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1293-1299.	3.3	84
40	Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1. <i>Journal of Molecular Endocrinology</i> , 2015, 54, 137-147.	1.1	83
41	Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance. <i>Oncologist</i> , 2013, 18, 850-864.	1.9	82
42	EGFR in melanoma: clinical significance and potential therapeutic target. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 492-502.	0.7	77
43	Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. <i>Cancers</i> , 2019, 11, 1597.	1.7	77
44	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. <i>Oncotarget</i> , 2015, 6, 24780-24796.	0.8	77
45	Safety and Efficacy of Hyperthermic Intraperitoneal Chemoperfusion with High-Dose Oxaliplatin in Patients with Peritoneal Carcinomatosis. <i>Annals of Surgical Oncology</i> , 2008, 15, 535-541.	0.7	74
46	Increased permeability of macroscopically normal small bowel in Crohn's disease. <i>Digestive Diseases and Sciences</i> , 1994, 39, 2170-2176.	1.1	73
47	Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol. <i>Cancers</i> , 2019, 11, 458.	1.7	73
48	Biologic therapies in the metastatic colorectal cancer treatment continuum – Applying current evidence to clinical practice. <i>Cancer Treatment Reviews</i> , 2012, 38, 397-406.	3.4	72
49	Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas. <i>BMC Cancer</i> , 2010, 10, 189.	1.1	70
50	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. <i>Cancer Treatment Reviews</i> , 2014, 40, 990-1004.	3.4	70
51	Anti-Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?. <i>Oncologist</i> , 2009, 14, 29-39.	1.9	69
52	Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. <i>British Journal of Cancer</i> , 2016, 114, 650-658.	2.9	69
53	Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2015, 51, 1231-1242.	1.3	68
54	Multidisciplinary management of patients with liver metastasis from colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 7215.	1.4	67

#	ARTICLE	IF	CITATIONS
55	Expression of SGLT1, Bcl-2 and p53 in Primary Pancreatic Cancer Related to Survival. <i>Cancer Investigation</i> , 2008, 26, 852-859.	0.6	65
56	Evaluation of small-bowel transit for solid and liquid test meal in healthy men and women. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1560-1566.	3.3	63
57	Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. <i>Redox Biology</i> , 2021, 42, 101949.	3.9	63
58	The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 22666-22679.	0.8	62
59	SARS-CoV-2 and cancer: Are they really partners in crime?. <i>Cancer Treatment Reviews</i> , 2020, 89, 102068.	3.4	60
60	Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. <i>Oncotarget</i> , 2017, 8, 56968-56979.	0.8	59
61	Methylation analysis of <i>E-cadherin</i> shows great promise as a biomarker for colorectal cancer. <i>Cancer Medicine</i> , 2019, 8, 2133-2145.	1.3	58
62	Deoxycytidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. <i>Cancer</i> , 2010, 116, 5200-5206.	2.0	57
63	Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2016, 68, 51-59.	1.3	56
64	Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. <i>Targeted Oncology</i> , 2017, 12, 97-109.	1.7	56
65	Paclitaxel- β -cyclodextrin complexes for hyperthermic peritoneal perfusion – Formulation and stability. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2007, 66, 391-397.	2.0	55
66	Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1188-1196.	0.4	54
67	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, e617-e629.	1.0	54
68	Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins. <i>Cancer Letters</i> , 2014, 354, 365-377.	3.2	53
69	Evaluation and consequences of heterogeneity in the circulating tumor cell compartment. <i>Oncotarget</i> , 2016, 7, 48625-48643.	0.8	53
70	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3568-3568.	0.8	53
71	APR-246 (PRIMA-1 MET) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. <i>Cancer Letters</i> , 2016, 375, 313-322.	3.2	51
72	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , 2019, 79, 1375-1394.	4.9	48

#	ARTICLE	IF	CITATIONS
73	Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. <i>International Journal of Molecular Sciences</i> , 2017, 18, 418.	1.8	47
74	Evidence for inflammatory bowel disease of a susceptibility locus on the X chromosome. <i>Gastroenterology</i> , 2001, 120, 834-840.	0.6	46
75	Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2019, 108, 26-36.	1.2	46
76	Cancer and the microbiome: potential applications as new tumor biomarker. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 317-330.	1.1	45
77	The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 121, 1-10.	2.0	45
78	Impact of Emergent Circulating Tumor DNA <i><i>RAS</i></i> Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5602-5609.	3.2	45
79	Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 991-1006.	1.1	44
80	Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	43
81	Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 6411-6420.	3.2	43
82	Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1 α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress. <i>Cancers</i> , 2018, 10, 126.	1.7	43
83	Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. <i>BMC Cancer</i> , 2009, 9, 112.	1.1	42
84	A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 213.	3.5	42
85	^{99m} Tc-(CO) ₃ His-Annexin A5 Micro-SPECT Demonstrates Increased Cell Death by Irinotecan During the Vascular Normalization Window Caused by Bevacizumab. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1786-1794.	2.8	41
86	Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, 170-178.e3.	1.0	41
87	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017, 82, 16-24.	1.3	40
88	Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2018, 17, e369-e379.	1.0	39
89	The art of obtaining a high yield of cell-free DNA from urine. <i>PLoS ONE</i> , 2020, 15, e0231058.	1.1	39
90	In Vivo Imaging of Apoptosis in Oncology: An Update. <i>Molecular Imaging</i> , 2011, 10, 7290.2010.00058.	0.7	38

#	ARTICLE	IF	CITATIONS
91	Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. <i>Oncolimmunology</i> , 2018, 7, e1407899.	2.1	38
92	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172.	0.8	38
93	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 987.	1.7	38
94	Comprehensive analysis of <i>KRAS</i> and <i>NRAS</i> mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).. <i>Journal of Clinical Oncology</i> , 2013, 31, 3617-3617.	0.8	37
95	<i>DFNA5</i> promoter methylation a marker for breast tumorigenesis. <i>Oncotarget</i> , 2017, 8, 31948-31958.	0.8	37
96	Follicle-Stimulating Hormone Receptor (FSHR): A Promising Tool in Oncology?. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 523-530.	1.6	36
97	Reducing Compounds Equivocally Influence Oxidation during Digestion of a High-Fat Beef Product, which Promotes Cytotoxicity in Colorectal Carcinoma Cell Lines. <i>Journal of Agricultural and Food Chemistry</i> , 2016, 64, 1600-1609.	2.4	36
98	Simultaneous targeting of <i>EGFR</i> , <i>HER2</i> , and <i>HER4</i> by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines. <i>Molecular Oncology</i> , 2018, 12, 830-854.	2.1	36
99	Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects. <i>Antioxidants</i> , 2020, 9, 1188.	2.2	36
100	Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. <i>International Journal of Colorectal Disease</i> , 2011, 26, 173-181.	1.0	35
101	Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response. <i>BMC Research Notes</i> , 2014, 7, 337.	0.6	35
102	Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study. <i>Clinical Cancer Research</i> , 2019, 25, 1216-1225.	3.2	35
103	Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma. <i>Cells</i> , 2021, 10, 2936.	1.8	35
104	Familial and sporadic inflammatory bowel disease: Different entities?. <i>Inflammatory Bowel Diseases</i> , 2000, 6, 314-320.	0.9	34
105	Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. <i>Oncolimmunology</i> , 2018, 7, e1440167.	2.1	33
106	Determination of the Potential Tumor-Suppressive Effects of Gsdme in a Chemically Induced and in a Genetically Modified Intestinal Cancer Mouse Model. <i>Cancers</i> , 2019, 11, 1214.	1.7	32
107	18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. <i>Gastroenterology</i> , 2003, 125, 1235-1245.	0.6	30
108	Systematic review and meta-analysis of local resection or transanal endoscopic microsurgery versus radical resection in stage I rectal cancer: A real standard?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 43-52.	2.0	30

#	ARTICLE	IF	CITATIONS
109	Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. <i>British Journal of Cancer</i> , 2018, 119, 303-312.	2.9	29
110	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	2.0	29
111	Safety and Antitumor Activity of Î±-PD-L1 Antibody as Monotherapy or in Combination with Î±-TIM-3 Antibody in Patients with Microsatellite Instabilityâ€œHigh/Mismatch Repairâ€œDeficient Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 6393-6404.	3.2	29
112	An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. <i>Targeted Oncology</i> , 2013, 8, 127-136.	1.7	28
113	Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer. <i>Cancer Letters</i> , 2015, 356, 872-879.	3.2	28
114	The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 737311.	2.2	28
115	The role of targeted therapy for gastrointestinal tumors. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 875-885.	1.4	27
116	Engineering monocyte-derived dendritic cells to secrete interferon-Î± enhances their ability to promote adaptive and innate anti-tumor immune effector functions. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 831-842.	2.0	27
117	Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 321-335.	1.2	27
118	Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: A multicenter Belgian phase II study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 1351-1356.	0.4	26
119	Expression Analysis on Archival Material Revisited. <i>Diagnostic Molecular Pathology</i> , 2013, 22, 59-64.	2.1	26
120	Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 113-124.	1.6	26
121	Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukinâ€œ15 treatment. <i>Clinical and Translational Immunology</i> , 2020, 9, e1165.	1.7	26
122	Cell-Free DNA From Metastatic Pancreatic Neuroendocrine Tumor Patients Contains Tumor-Specific Mutations and Copy Number Variations. <i>Frontiers in Oncology</i> , 2018, 8, 467.	1.3	25
123	Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status. <i>British Journal of Cancer</i> , 2020, 123, 752-761.	2.9	25
124	Exclusion of Linkage of Crohn's Disease to Previously Reported Regions on Chromosomes 12, 7, and 3 in the Belgian Population Indicates Genetic Heterogeneity. <i>Inflammatory Bowel Diseases</i> , 2000, 6, 165-170.	0.9	24
125	Forcing Cancer Cells to Commit Suicide. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 395-407.	0.7	24
126	The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors. <i>Current Pharmaceutical Design</i> , 2013, 19, 907-917.	0.9	24

#	ARTICLE	IF	CITATIONS
127	The Gasdermin E gene Potential as a Pan-Cancer Biomarker, While Discriminating between Different Tumor Types. <i>Cancers</i> , 2019, 11, 1810.	1.7	24
128	Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma. <i>Medicinal Research Reviews</i> , 2022, 42, 112-155.	5.0	24
129	Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA387-LBA387.	0.8	24
130	Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, R109-R130.	1.6	24
131	Expression profiling of migrated and invaded breast cancer cells predicts early metastatic relapse and reveals KrÄppel-like factor 9 as a potential suppressor of invasive growth in breast cancer. <i>Oncoscience</i> , 2014, 1, 69-81.	0.9	24
132	Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 665-672.	1.1	23
133	Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation. <i>Future Oncology</i> , 2010, 6, 1485-1496.	1.1	23
134	Study protocol for a randomized controlled trial: tongue strengthening exercises in head and neck cancer patients, does exercise load matter?. <i>Trials</i> , 2015, 16, 395.	0.7	23
135	A video-game based cognitive training for breast cancer survivors with cognitive impairment: A prospective randomized pilot trial. <i>Breast</i> , 2020, 53, 23-32.	0.9	23
136	Psychometric Evaluation of the FACT Colorectal Cancer Symptom Index (FCSI-9): Reliability, Validity, Responsiveness, and Clinical Meaningfulness. <i>Oncologist</i> , 2010, 15, 308-316.	1.9	22
137	Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants. <i>Tumor Biology</i> , 2017, 39, 101042831769432.	0.8	22
138	Proxies of quality of life in metastatic colorectal cancer: analyses in the RECURSE trial. <i>ESMO Open</i> , 2017, 2, e000261.	2.0	22
139	Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. <i>Future Oncology</i> , 2018, 14, 1629-1645.	1.1	22
140	RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2183.	1.8	22
141	Single-Photon Emission Computed Tomographic Imaging of the Early Time Course of Therapy-Induced Cell Death Using Technetium 99m Tricarbonyl His-Annexin A5 in a Colorectal Cancer Xenograft Model. <i>Molecular Imaging</i> , 2012, 11, 7290.2011.00034.	0.7	22
142	Targeting hedgehog signaling in pancreatic ductal adenocarcinoma. , 2022, 236, 108107.		22
143	Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: An experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. <i>Oncology Reports</i> , 2009, 22, 105-13.	1.2	21
144	The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines. <i>BMC Research Notes</i> , 2015, 8, 203.	0.6	21

#	ARTICLE	IF	CITATIONS
145	Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2001-2010.	1.2	20
146	Study protocol for a randomized controlled trial: prophylactic swallowing exercises in head-and-neck cancer patients treated with (chemo)radiotherapy (PRESTO trial). <i>Trials</i> , 2020, 21, 237.	0.7	20
147	Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy – The Role of Liquid Biopsy in Unraveling the Puzzle. <i>Cancers</i> , 2021, 13, 1675.	1.7	20
148	Tc-99m HMPAO white blood cell scintigraphy in the assessment of the extent and severity of an acute exacerbation of ulcerative colitis. <i>Clinical Nuclear Medicine</i> , 2001, 26, 99-104.	0.7	19
149	Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population. <i>European Journal of Cancer</i> , 2008, 44, 2288-2295.	1.3	19
150	In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells. <i>Nuclear Medicine and Biology</i> , 2010, 37, 965-975.	0.3	19
151	Panitumumab in Combination With Cytotoxic Chemotherapy for the Treatment of Metastatic Colorectal Carcinoma. <i>Clinical Colorectal Cancer</i> , 2012, 11, 14-23.	1.0	19
152	PDX1 DNA Methylation Distinguishes Two Subtypes of Pancreatic Neuroendocrine Neoplasms with a Different Prognosis. <i>Cancers</i> , 2020, 12, 1461.	1.7	19
153	Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor. <i>American Journal of Cancer Research</i> , 2015, 5, 1921-38.	1.4	19
154	Neoadjuvant Chemoradiation Versus Hyperfractionated Accelerated Radiotherapy in Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 424-431.	0.7	18
155	Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status. <i>Drugs</i> , 2015, 75, 731-748.	4.9	18
156	Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. <i>ESMO Open</i> , 2018, 3, e000297.	2.0	18
157	In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small cell lung cancer reveals a role for the tumor suppressor p53. <i>Molecular Oncology</i> , 2019, 13, 1196-1213.	2.1	17
158	Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3507-3507.	0.8	17
159	The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. <i>Oncotarget</i> , 2016, 7, 73960-73970.	0.8	17
160	MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 197-203.	1.4	16
161	Expression Analysis on Archival Material. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 203-211.	2.1	16
162	LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases—a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. <i>BMC Cancer</i> , 2012, 12, 144.	1.1	16

#	ARTICLE	IF	CITATIONS
163	The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0138341.	1.1	16
164	Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis. Oncologist, 2016, 21, 59-71.	1.9	16
165	Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up. Clinical Cancer Research, 2022, 28, 338-349.	3.2	16
166	How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?. Expert Opinion on Biological Therapy, 2014, 14, 743-748.	1.4	15
167	Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 229-238.	0.7	15
168	Towards risk-stratified colorectal cancer screening. Adding risk factors to the fecal immunochemical test: Evidence, evolution and expectations. Preventive Medicine, 2019, 126, 105746.	1.6	15
169	Follow up analysis by exosomal miRNAs in EGFR mutated non-small cell lung cancer (NSCLC) patients during osimertinib (AZD9291) treatment: A potential prognostic biomarker tool.. Journal of Clinical Oncology, 2016, 34, e23035-e23035.	0.8	15
170	The intriguing interplay between therapies targeting the epidermal growth factor receptor, the hypoxic microenvironment and hypoxia-inducible factors. Current Pharmaceutical Design, 2013, 19, 907-17.	0.9	15
171	Noninvasive Monitoring of Therapy-Induced Microvascular Changes in a Pancreatic Cancer Model Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging with P846, a New Low-Diffusible Gadolinium-Based Contrast Agent. Radiation Research, 2011, 175, 10-20.	0.7	14
172	Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2011, 24, 225-232.	1.1	14
173	Next generation exome sequencing of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1 reveals different lineages. Cancer Genetics, 2015, 208, 523.	0.2	14
174	Evolution of self-perceived swallowing function, tongue strength and swallow-related quality of life during radiotherapy in head and neck cancer patients. Head and Neck, 2019, 41, 2197-2207.	0.9	14
175	Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biology and Therapy, 2020, 21, 891-898.	1.5	14
176	AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients. Supportive Care in Cancer, 2021, 29, 859-867.	1.0	14
177	Immunoglobulin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. European Journal of Cancer, 2021, 148, 328-339.	1.3	14
178	Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer, 2013, 13, 190.	1.1	11
179	Incorporating Anti-VEGF Pathway Therapy as a Continuum of Care in Metastatic Colorectal Cancer. Current Treatment Options in Oncology, 2015, 16, 18.	1.3	11
180	Feasibility of an interactive electronic self-report tool for oral cancer therapy in an outpatient setting. Supportive Care in Cancer, 2016, 24, 3567-3571.	1.0	11

#	ARTICLE	IF	CITATIONS
181	Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia. <i>Journal of Cancer</i> , 2017, 8, 1441-1452.	1.2	11
182	Risk stratification for colorectal neoplasia detection in the Flemish colorectal cancer screening programme. <i>Cancer Epidemiology</i> , 2018, 56, 90-96.	0.8	11
183	Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform. <i>ESMO Open</i> , 2020, 5, e000817.	2.0	11
184	The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy. <i>Frontiers in Oncology</i> , 2021, 11, 697967.	1.3	11
185	Retention of the In Vitro Radiosensitizing Potential of Gemcitabine Under Anoxic Conditions, in p53 Wild-Type and p53-Deficient Non-Small-Cell Lung Carcinoma Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 558-566.	0.4	10
186	The presence of Y chromosomal deoxyribonucleic acid in the female vaginal swab: Possible implications for human papillomavirus testing. <i>Cancer Epidemiology</i> , 2011, 35, 101-103.	0.8	10
187	Feasibility of tongue strength measurements during (chemo)radiotherapy in head and neck cancer patients. <i>Supportive Care in Cancer</i> , 2017, 25, 3417-3423.	1.0	10
188	Exosomes in lung cancer liquid biopsies: Two sides of the same coin?. <i>Lung Cancer</i> , 2017, 104, 134-135.	0.9	10
189	Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2019, 20, 333-351.	2.6	10
190	Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib. <i>Cancers</i> , 2019, 11, 98.	1.7	10
191	The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care. <i>Oncologist</i> , 2020, 25, e1-e4.	1.9	9
192	Genome-wide DNA methylation profiling and identification of potential pan-cancer and tumor-specific biomarkers. <i>Molecular Oncology</i> , 2022, 16, 2432-2447.	2.1	9
193	Clinical procedure for colon carcinoma tissue sampling directly affects the cancer marker-capacity of VEGF family members. <i>BMC Cancer</i> , 2012, 12, 515.	1.1	8
194	Dilemma in metastatic colorectal cancer: VEGF versus EGFR targeting. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 869-871.	1.5	8
195	Antineoplastic therapy-induced pulmonary toxicity. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 997-1006.	1.1	8
196	Tumorbank@uza: A Collection of Tissue, Fluid Samples and Associated Data of Oncology Patients for the Use in Translational Research. <i>Open Journal of Bioresources</i> , 2018, 5, .	1.5	8
197	Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 229-238.	0.7	8
198	An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries. <i>Supportive Care in Cancer</i> , 2017, 25, 2823-2832.	1.0	7

#	ARTICLE	IF	CITATIONS
199	Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. <i>Cancers</i> , 2019, 11, 1893.	1.7	7
200	High mortality of cancer patients in times of SARS-CoV-2: Do not generalize!. <i>European Journal of Cancer</i> , 2020, 138, 225-227.	1.3	7
201	Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G. <i>Cancers</i> , 2020, 12, 1715.	1.7	7
202	Status of Active Specific Immunotherapy for Stage II, Stage III, and Resected Stage IV Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 380-390.	1.0	6
203	The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein. <i>BMC Cancer</i> , 2014, 14, 594.	1.1	6
204	Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. <i>Drugs</i> , 2015, 75, 1739-1756.	4.9	6
205	Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 339-349.	1.1	6
206	Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to KAPhne Prognostic Category and BRAF Mutation Status. <i>Clinical Colorectal Cancer</i> , 2018, 17, 50-57.e8.	1.0	6
207	Abstract LB-174: Use of massively parallel, next-generation sequencing to identify gene mutations beyond ERAS that predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC). , 2010, , .		6
208	Digestive oncologist in the gastroenterology training curriculum. <i>World Journal of Gastroenterology</i> , 2011, 17, 1109.	1.4	6
209	Unusual Serum Electrophoresis Pattern in a Woman with Pancreatic Carcinoma. <i>Clinical Chemistry</i> , 2008, 54, 1572-1574.	1.5	5
210	Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 471-478.	1.4	5
211	Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103190.	2.0	5
212	The tele-transition of toxicity management in routine oncology care during the severe acute respiratory syndrome (SARS-CoV-2) pandemic. <i>British Journal of Cancer</i> , 2021, 124, 1366-1372.	2.9	5
213	Biosimilars in an era of rising oncology treatment options. <i>Future Oncology</i> , 2021, 17, 3881-3892.	1.1	5
214	Genetic-wide scanning in a Belgian IBD population reveals novel linkages and validates previous linkages. <i>Gastroenterology</i> , 2001, 120, A456.	0.6	4
215	MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients. <i>Journal of Cancer</i> , 2017, 8, 2154-2162.	1.2	4
216	The immunologic aspects in hormone receptor positive breast cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100207.	0.7	4

#	ARTICLE	IF	CITATIONS
217	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy, 2020, 20, 251-270.	1.1	4
218	Excellent Response to MEK Inhibition in an <i>AGK-BRAF</i> Gene Fusion Driven Carcinoma: Case Report and Literature Review. Anticancer Research, 2022, 42, 373-379.	0.5	4
219	Future directions for selective internal radiation therapy in colorectal cancer. European Journal of Cancer, Supplement, 2012, 10, 15-17.	2.2	3
220	Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward. Gastroenterology Research and Practice, 2015, 2015, 1-9.	0.7	3
221	The Oncology Data Network (ODN): Methodology, Challenges, and Achievements. Oncologist, 2020, 25, e1428-e1432.	1.9	3
222	Clinical outcomes and emergent circulating tumor (ct)DNA RAS mutations and allele fraction for patients with metastatic colorectal cancer (mCRC) treated with panitumumab from the ASPCCCT study.. Journal of Clinical Oncology, 2017, 35, 3584-3584.	0.8	3
223	BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat) ETQq110.784314rgBT/Overlock phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAF V600E mCRC. Journal of Clinical Oncology, 2017, 35, 3583-3583.	0.8	3
224	The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors. Current Pharmaceutical Design, 2012, 19, 907-917.	0.9	3
225	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. JNCI Cancer Spectrum, 2022, 6, .	1.4	3
226	FOLFIRI with cetuximab or bevacizumab: FIRE-3. Lancet Oncology, The, 2014, 15, e582-e583.	5.1	2
227	ASPCCCT: panitumumab versus cetuximab for colorectal cancer – Authors' reply. Lancet Oncology, The, 2014, 15, e303.	5.1	2
228	Should Flanders consider lowering its target age for colorectal cancer screening to 45–49?. Cancer Epidemiology, 2019, 61, 172-175.	0.8	2
229	Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Clinical Colorectal Cancer, 2019, 18, 245-256.e5.	1.0	2
230	Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready to Improve Clinical Outcome?. Cancers, 2020, 12, 299.	1.7	2
231	Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial. Clinical Colorectal Cancer, 2021, 20, 326-333.	1.0	2
232	Profiling circulating tumor (ct)DNA mutations after panitumumab treatment in patients with refractory metastatic colorectal cancer (mCRC) from the phase III ASPCCCT study.. Journal of Clinical Oncology, 2017, 35, 3523-3523.	0.8	2
233	Will the medical student in the team please stand up?. Lancet Oncology, The, 2012, 13, 757-758.	5.1	1
234	Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 250-260.	1.0	1

#	ARTICLE	IF	CITATIONS
235	Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 380-394.	1.0	1
236	Case histories in unresectable liver-dominant metastatic colorectal cancer. <i>Future Oncology</i> , 2014, 10, 41-47.	1.1	1
237	Relationships Between KRAS Gene Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	1
238	Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy. <i>PLoS ONE</i> , 2021, 16, e0252646.	1.1	1
239	Expression profiles of miR-196, miR-132, miR-146a, and miR-134 in human colorectal cancer tissues in accordance with their clinical significance. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1162-1170.	1.0	1
240	Development, Testing, and Implementation of the Belgian Patient Reported Experience Measure for Pancreatic Cancer Care (PREPARE) Project: Protocol for a Multi-Method Research Project. <i>JMIR Research Protocols</i> , 2022, 11, e29004.	0.5	1
241	Combined Effect of EPO and Radiotherapy on the Expression of Endogenous Molecular Markers of Tumor Metabolism and Metastasis. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 565-572.	0.7	0
242	Cardiovascular Risk Status Can Influence the Colorectal Cancer Screening Strategy. <i>Digestion</i> , 2010, 81, 18-19.	1.2	0
243	Indications for Locoregional Tumor Therapies: CRC Liver Metastases. , 2018, , 83-106.		0
244	Abstract 5212: Preclinical study of the cytotoxic effect of nutlin-3a as monotherapy or in combination with gemcitabine in non-small cell lung cancer cell lines.. , 2013, , .		0
245	Abstract 448: Molecular analysis of BRAF gene and PTEN gene expression in metastatic colorectal cancer patients: Feasibility study. , 2014, , .		0
246	Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3538-3538.	0.8	0
247	Abstract 258: Is P53 the up-and-coming predictive biomarker for volasertib treatment in NSCLC. , 2016, , .		0
248	Innovative molecular targeted agents in hepatocellular carcinoma: new gladiators on the arena. <i>Minerva Surgery</i> , 2017, 72, 206-218.	0.1	0
249	Assessing outcome differences in the second line treatment of metastatic colorectal cancer (mCRC): An ARCAD analysis comparing sequence after first line trials (SAFL) and dedicated second line trials (DSLTL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3554-3554.	0.8	0
250	Baseline cell-free DNA (cfDNA) and metabolic tumor volume (MTV) independently predict outcome in metastatic chemorefractory colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11569-11569.	0.8	0